The pituitary cancer market covers products that are used in the treatment of pituitary cancers. The pituitary gland, located at the base of the brain, secretes hormones that control growth, metabolism, and various reproductive functions of the body. Pituitary cancers arise due to abnormal cell growth within the pituitary gland, known as pituitary adenoma, which if untreated can become malignant. Currently available treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy drugs.
The global pituitary cancer market is estimated to be valued at US$ 457.31 Mn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period 2024 to 2031.
Key Takeaways
Key players
Key players operating in the pituitary cancer market are Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Endocyte, RECORDATI GROUP, Camurus AB, Endeavor Biomedicines, Inc., and Debiopharm International SA.
Growing Demand
The growing prevalence of pituitary adenoma and subsequent rise in pituitary cancer cases globally is a major factor driving the Pituitary Cancer Market Demand According to the National Cancer Institute, pituitary adenoma accounts for 10-25% of all primary brain tumors in the US.
Global Expansion
Regional expansions and new product launches by key players are helping increase geographic footprint as well as widening the treatment options available in the pituitary cancer market. Increasing access to healthcare facilities in developing countries will further support the market growth over the forecast period.
Market key trends
The growing target therapy drug approvals will be a key trend shaping the future outlook of the Pituitary Cancer Market Size And Trends Advances in understanding the molecular mechanisms of pituitary tumors initiation and progression have ushered the development of targeted drug therapies. Drugs targeting specific causative genetic mutations and aberrant cellular signaling pathways in pituitary cancers are likely to gain more approvals in the coming years.
Porter’s Analysis
Threat of new entrants: Low barrier for new entrants as specialized skills are required for research and development.
Bargaining power of buyers: Buyers have low bargaining power as most of pituitary cancer drugs are patented drugs.
Bargaining power of suppliers: Suppliers have moderate bargaining power as raw material suppliers for pituitary cancer drugs manufacturing depends on a handful of suppliers.
Threat of new substitutes: Limited threat of substitutes as pituitary cancer treatment requires specialized drugs.
Competitive rivalry: High competitive rivalry exists among the major players to develop advanced drugs for effective pituitary cancer treatment.
Geographical regions
North America holds the major share of the pituitary cancer market in terms of value owing to advanced healthcare infrastructure and presence of key market players in the region.
Asia Pacific is expected to be the fastest growing region during the forecast period due to growing healthcare expenditure, increasing awareness about pituitary cancer, and rising geriatric population susceptible to develop pituitary cancer.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it